NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
7.04
Dollar change
+1.15
Percentage change
19.52
%
Index- P/E- EPS (ttm)-1.63 Insider Own70.81% Shs Outstand6.32M Perf Week8.31%
Market Cap44.48M Forward P/E- EPS next Y- Insider Trans184.31% Shs Float1.84M Perf Month-27.57%
Enterprise Value34.68M PEG- EPS next Q- Inst Own0.81% Short Float0.73% Perf Quarter-49.68%
Income-5.86M P/S- EPS this Y- Inst Trans2.26% Short Ratio0.88 Perf Half Y-59.02%
Sales0.00M P/B3.91 EPS next Y- ROA-37.35% Short Interest0.01M Perf YTD-48.50%
Book/sh1.80 P/C4.27 EPS next 5Y- ROE-86.28% 52W High36.00 -80.44% Perf Year348.12%
Cash/sh1.65 P/FCF- EPS past 3/5Y64.76% 41.35% ROIC-51.38% 52W Low1.44 388.89% Perf 3Y-65.77%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- -17.34% Gross Margin- Volatility17.01% 10.65% Perf 5Y-98.34%
Dividend TTM- EV/Sales- EPS Y/Y TTM76.04% Oper. Margin- ATR (14)0.89 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.91 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)39.09 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio2.91 EPS Q/Q201.59% SMA20-15.58% Beta3.58 Target Price10.00
Payout- Debt/Eq0.05 Sales Q/Q-100.00% SMA50-27.28% Rel Volume276.33 Prev Close5.89
Employees7 LT Debt/Eq0.00 EarningsMar 18 AMC SMA200-28.90% Avg Volume15.38K Price7.04
IPOMay 22, 2018 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume4,250,643 Change19.52%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Jun-27-25 04:01PM
May-28-25 04:58PM
May-05-25 08:00AM
Apr-22-25 09:21AM
Apr-14-25 06:11PM
07:42PM Loading…
Apr-11-25 07:42PM
Mar-18-25 04:01PM
Mar-13-25 04:08PM
Jan-23-25 12:17AM
Jan-22-25 04:01PM
Dec-26-24 08:08PM
Dec-21-24 01:48PM
Dec-20-24 04:42PM
Nov-14-24 04:01PM
Sep-18-24 04:01PM
06:53PM Loading…
Sep-09-24 06:53PM
Aug-26-24 09:08AM
Aug-19-24 10:31AM
Aug-15-24 10:31AM
Aug-13-24 04:01PM
Aug-08-24 04:27PM
Aug-02-24 07:34AM
Aug-01-24 04:01PM
Jul-26-24 07:36AM
Jun-17-24 09:53PM
04:01PM
Jun-06-24 09:52PM
04:01PM
May-29-24 07:39AM
May-23-24 04:01PM
09:52PM Loading…
May-16-24 09:52PM
04:08PM
Apr-22-24 04:01PM
Feb-06-24 07:05AM
Feb-05-24 04:01PM
Dec-08-23 08:40AM
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HiTron Systems Inc.10% OwnerDec 26 '24Buy3.002,900,0008,700,0003,333,333Mar 26 05:41 PM
DGP Co., Ltd.10% OwnerSep 12 '24Buy3.00237,223711,669849,223Sep 16 09:41 PM